Current safety frameworks often overlook microbiome-immune interactions. This editorial examines the gap between physicochemical toxicity and biological stability, proposing specific validation experiments to assess material impact on skin barrier homeostasis.
Framework Misalignment in Safety Assessment
The Safe and Sustainable by Design framework prioritizes traditional toxicology endpoints like cytotoxicity and environmental persistence. These static physicochemical metrics do not inherently capture the dynamic nature of the skin's biological barrier, which relies on complex host-microbe interactions.
Consequently, a material deemed safe based on low toxicity may still disrupt immune homeostasis. The absence of specific microbiome endpoints in standard assessments creates a blind spot where chemical safety does not equate to biological compatibility.
Physicochemical Interactions with Barrier Lipids
Nanomaterials such as cellulose fibers can alter the local microenvironment by interacting with stratum corneum lipids and sebum. These interactions may modify local pH levels or lipid arrangement, which are critical for maintaining the chemical barrier's integrity.
Such changes can indirectly affect microbial enzyme activity, specifically lipases that generate free fatty acids. If these metabolic products are reduced, the chemical barrier's ability to support immune signaling and inhibit pathogens may be compromised without direct cytotoxicity.
Immune Signaling and Adaptive Stability
Skin microbiota regulate host immunity through pattern recognition receptors like TLR2, influencing the production of antimicrobial peptides and cytokines. This innate signaling is essential for promoting regulatory T-cell accumulation, which prevents excessive inflammatory responses to commensal bacteria.
Standard in vitro models often assess direct cell toxicity but rarely evaluate these complex signaling cascades. Without measuring specific immune markers or T-cell dynamics, the potential for a material to disrupt adaptive immune stability remains unquantified in current safety protocols.
Validation Experiments and Evidence Boundaries
To address these gaps, validation must include microbiome-host co-culture systems. Key experiments should measure microbial diversity via sequencing, quantify metabolic products like short-chain fatty acids, and assess immune markers such as hBD-2 expression and Treg cell proportions in 3D skin models.
Failure signals include significant reductions in microbial diversity or abnormal shifts in immune cell ratios. However, these in vitro findings cannot be directly extrapolated to human clinical outcomes, as they do not fully replicate the dynamic complexity of in vivo skin regions or individual variability.
Editorial and use boundary
Evidence is limited to in vitro models and theoretical frameworks; no human clinical efficacy or safety claims are made.